# NeuroVasc Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neurovasc-technologies

- Industry: Medical Devices & Equipment
- Headquarters: Laguna Hills, US
- Website: www.neurovasctechnologies.com
- Total disclosed funding: $6.3M
- Latest round: Series B (May 21, 2018)
- Investors on record: 1

## About

NeuroVasc Technologies, Inc. is a medical device company focused on innovative solutions for neurovascular treatments, specifically aimed at enhancing patient outcomes in stroke care.Founded in 2015 in Laguna Hills, US, NeuroVasc Technologies specializes in neurovascular treatment devices. The company has completed 5 deals, with the most recent funding round occurring on February 27, 2020, where it raised USD 34 mn led by Shandong Weigao Group Medical Polymer Co., Limited. The CEO of the company is Wanli Jiang.NeuroVasc Technologies specializes in the design and development of innovative neurovascular treatment devices, including advanced catheter-based technologies like the eNVi-SR™, eNVoke™, and eNVac™ systems. These products are designed for mechanical thrombectomy and aspiration procedures to effectively remove blood clots from the neurovascular system. The company serves a diverse client base, including hospitals and healthcare providers across more than 35 countries, ensuring improved access to critical stroke interventions in regions such as Europe, Asia, and South America.NeuroVasc Technologies operates on a B2B model, primarily engaging with healthcare institutions to supply their proprietary neurovascular devices. Sales transactions typically involve direct partnerships with hospitals and medical facilities, where devices are purchased per procedure or through contractual agreements for bulk supply. Their flagship products are integral to these transactions, enabling healthcare providers to offer advanced stroke treatment solutions. Pricing structures are based on specific products utilized and volume agreements, which facilitate the integration of these innovative devices into treatment protocols without compromising patient care.NeuroVasc Technologies plans to expand its product line with new neurovascular devices targeted for release in the coming years. The company is also looking to enter new markets, particularly in Asia and South America, by the end of 2022. The recent funding of USD 34 mn will support these initiatives, enabling the development of new products and the expansion into these targeted geographic regions.

## Funding rounds

- Series B, May 21, 2018, $6.3M — ShangBay Capital

## Investors

- ShangBay Capital (https://capitalatlas.ai/funds/shangbay-capital) — Series B